文献速递毛发、甲与色素性疾病皮肤肿瘤

癌症患者持续性放射性脱发的评估与治疗结局

Assessment and Treatment Outcomes of Persistent Radiation-Induced Alopecia in Patients With Cancer.
PubMed 文献 · JAMA Dermatol · 2020-01-01

该回顾性队列研究纳入71例原发中枢神经系统肿瘤或头颈部肉瘤患者,评估持续性放射性脱发(pRIA)的临床与毛发镜特征、 scalp 放疗剂量反应关系及外用米诺地尔疗效。结果显示脱发严重度与剂量和质子照射相关,半数患者出现重度脱发的剂量为36.1 Gy,82%患者对外用米诺地尔有反应。

要点

  • pRIA呈剂量依赖性,头皮放疗剂量越高脱发越重。
  • 质子照射与更严重的脱发严重度相关。
  • 外用米诺地尔5%可使多数患者脱发改善。

核心结论

  • 原发中枢神经系统肿瘤或头颈部肉瘤患者的持续性放射性脱发呈剂量依赖性现象,具有独特的临床和毛发镜特征。
  • 外用米诺地尔和操作干预可能对pRIA治疗有益。

研究设计与样本

  • 回顾性队列研究,纳入2011年1月1日至2019年1月30日两家大型三级医院和综合癌症中心的71例原发中枢神经系统肿瘤或头颈部肉瘤儿童和成人患者。
  • 通过标准化头皮临床照片、毛发镜图像和放疗计划评估临床与毛发镜特征、头皮放疗剂量反应关系及外用米诺地尔反应。

主要发现

  • 71例患者中位年龄27岁(范围4-75岁),女性51例(72%);64例(90%)为中枢神经系统肿瘤,7例(10%)为头颈部肉瘤。
  • 70例中40例(56%)脱发严重度为1级,54例中局部型29例(54%)、弥漫型13例(24%)、混合型12例(22%)。
  • 中位估计头皮放疗剂量为39.6 Gy(范围15.1-50.0 Gy);更高剂量(OR 1.15;95%CI 1.04-1.28)和质子照射(OR 5.7;95%CI 1.05-30.8)与更严重的脱发相关(P < .001)。
  • 50%患者出现重度(2级)脱发的估计剂量为36.1 Gy(95%CI 33.7-39.6 Gy)。
  • 主要毛发镜特征包括白色斑片(28例中16例,57%);15例患者毛发干直径与头皮剂量负相关(相关系数-0.624;P = .01),毛发密度与剂量关联无统计学意义(-0.381;P = .16)。

临床怎么用

  • 对接受头皮放疗的癌症患者应评估持续性脱发,关注放疗剂量和照射方式(如质子照射)对脱发严重度的影响。
  • 外用米诺地尔5%可作为pRIA的治疗选择,部分患者可考虑毛发移植或整形外科重建。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Persistent radiation-induced alopecia (pRIA) and its management have not been systematically described. OBJECTIVE: To characterize pRIA in patients with primary central nervous system (CNS) tumors or head and neck sarcoma. DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study of patients from January 1, 2011, to January 30, 2019, was conducted at 2 large tertiary care hospitals and comprehensive cancer centers. Seventy-one children and adults diagnosed with primary CNS tumors or head and neck sarcomas were evaluated for pRIA. MAIN OUTCOMES AND MEASURES: The clinical and trichoscopic features, scalp radiation dose-response relationship, and response to topical minoxidil were assessed using standardized clinical photographs of the scalp, trichoscopic images, and radiotherapy treatment plans. RESULTS: Of the 71 patients included (median [range] age, 27 [4-75] years; 51 female [72%]), 64 (90%) had a CNS tumor and 7 (10%) had head and neck sarcoma. Alopecia severity was grade 1 in 40 of 70 patients (56%), with localized (29 of 54 [54%]), diffuse (13 of 54 [24%]), or mixed (12 of 54 [22%]) patterns. The median (range) estimated scalp radiation dose was 39.6 (15.1-50.0) Gy; higher dose (odds ratio [OR], 1.15; 95% CI, 1.04-1.28) and proton irradiation (OR, 5.7; 95% CI, 1.05-30.8) were associated with greater alopecia severity (P < .001), and the dose at which 50% of patients were estimated to have severe (grade 2) alopecia was 36.1 Gy (95% CI, 33.7-39.6 Gy). Predominant trichoscopic features included white patches (16 of 28 [57%]); in 15 patients, hair-shaft caliber negatively correlated with scalp dose (correlation coefficient, -0.624; P = .01). The association between hair density and scalp radiation dose was not statistically significant (-0.381; P = .16). Twenty-eight of 34 patients (82%) responded to topical minoxidil, 5% (median follow-up, 61 [interquartile range, 21-105] weeks); 4 of 25 (16%) topical minoxidil recipients with clinical images improved in severity grade. Two patients responded to hair transplantation and 1 patient responded to plastic surgical reconstruction. CONCLUSIONS AND RELEVANCE: Persistent radiation-induced alopecia among patients with primary CNS tumors or head and neck sarcomas represents a dose-dependent phenomenon that has distinctive clinical and trichoscopic features. The findings of this study suggest that topical minoxidil and procedural interventions may have benefit in the treatment of pRIA.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Phillips GS, Freret ME, Friedman DN, et al. Assessment and Treatment Outcomes of Persistent Radiation-Induced Alopecia in Patients With Cancer. JAMA Dermatol. 2020. PMID: 32756880. doi:10.1001/jamadermatol.2020.2127

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。